IRX Therapeutics Inc, Farmingdale, NY, USA.
Ann N Y Acad Sci. 2010 Apr;1194:162-8. doi: 10.1111/j.1749-6632.2010.05475.x.
Thymosin alpha1 (Talpha1) is a 28 amino acid biologically active protein with pleiotropic immune enhancing activity. IRX-2 is a primary cell-derived biologic containing multiple cytokines that enhance dendritic cell maturation, promote T-cell growth and differentiation, and inhibit tumor-mediated apoptosis of T cells. IRX-2 is being developed as an immunotherapeutic agent as a novel T-cell adjuvant platform for vaccines as well. Based on their biological activities, thymosin alpha1 and IRX-2 were predicted to exhibit synergistic effects when evaluated in animal and human studies. In animal studies, the combination of IRX-2 and Talpha1 (IRX-3) increased T-cell numbers compared to either alone during recovery from hydrocortisone mediated reduction. IRX-3 further enhanced reduction in tumor burden following chemotherapy compared to IRX-2. Based on these studies, IRX-3 is predicted to be especially important in a setting where reversal of immune suppression due to the presence of tumor, irradiation, and/or chemotherapy is likely to be an important factor in cytokine activity.
胸腺肽α1（Talpha1）是一种具有多种免疫增强活性的 28 个氨基酸生物活性蛋白。IRX-2 是一种源自原代细胞的生物制剂，包含多种细胞因子，可增强树突状细胞成熟，促进 T 细胞生长和分化，并抑制肿瘤介导的 T 细胞凋亡。IRX-2 被开发为一种免疫治疗剂，作为一种新型的 T 细胞佐剂平台用于疫苗。基于它们的生物学活性，胸腺肽α1 和 IRX-2 在动物和人类研究中被预测会表现出协同作用。在动物研究中，与单独使用相比，IRX-2 和 Talpha1（IRX-3）的组合在从氢化可的松介导的减少中恢复时增加了 T 细胞数量。IRX-3 进一步增强了与 IRX-2 相比，化疗后肿瘤负担的减少。基于这些研究，IRX-3 预计在由于肿瘤、辐射和/或化疗存在而逆转免疫抑制的情况下特别重要，因为这可能是细胞因子活性的重要因素。
